A new study from the laboratory of Frederick Alt, PhD, of the Program in Cellular and Molecular Medicine (PCMM) at Boston Children’s Hospital reveals yet another way in which chromatin regulation — changing the configuration of our DNA and its packaging — enables our immune systems to produce its wide-ranging arsenal of antibodies.
In September in the journal Nature, the Alt lab demonstrated how the formation of new loops in chromatin, known as loop extrusion, facilitates the process of V(D)J recombination, allowing bits of genetic code to be mixed and matched to generate new antibodies. The new study, published in Nature on October 30, finds that chromatin looping is also involved in another major method of antibody diversification, known as class switching.
Once V(D)J recombination assembles a specific antibody against a pathogen, class switching adjusts the class of antibody depending on where the infection is located and what kind of response is needed. For example, an infection in the mouth might trigger B cells to make IgA antibodies, found in mucous membranes, instead of IgM antibodies, found mainly in the blood and lymph fluid.
“Until now the mechanism of class switching was totally mysterious,” says Alt.
Together, the papers establish antibody formation as a poster child for the emerging field of chromatin loop extrusion and gene regulation — in which far-flung parts of the genome come together to create a rich repertoire of antibodies. “Loop extrusion contributes to both processes, but in totally different ways,” says Alt.
Related Posts :
Targeted small-molecule agent shows early promise against a dangerous infant leukemia
Leukemias involving reshuffling or rearrangement of the mixed lineage leukemia (MLL) gene, known as MLL-rearranged or MLL-r leukemias, account for 70 ...
Protecting against HIV by tricking the immune system
In making an HIV vaccine, a major goal is to stimulate production of broadly neutralizing antibodies that can fight multiple ...
A big step toward curbing graft-vs.-host disease after bone marrow transplant
A drug used for rheumatoid arthritis has moved a step closer to FDA approval for a desperately needed new use. ...
Boosting host immune defenses to treat tuberculosis
Current treatment regimens for Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, are long, complex, and hard for people to ...